{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T01:53:02Z","timestamp":1791078782996,"version":"4.1.0"},"reference-count":90,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[1999,10,1]],"date-time":"1999-10-01T00:00:00Z","timestamp":938736000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[1999,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Bisphosphonates have emerged as a valuable treatment for postmenopausal osteoporosis. Bisphosphonate treatment is usually accompanied by a 3\u20136% gain in bone mineral density (BMD) during the first year of treatment and by a decrease in bone turnover. Despite low bone turnover, BMD continues to increase slowly beyond the first year of treatment. There is evidence that bisphosphonates not only increase bone volume but also enhance secondary mineralization. The present study was conducted to address this issue and to compare the effects of continuous and intermittent bisphosphonate therapy on static and dynamic parameters of bone structure, formation, and resorption and on mineral properties of bone. Sixty dogs were ovariohysterectomized (OHX) and 10 animals were sham-operated (Sham). Four months after surgery, OHX dogs were divided in six groups (n = 10 each). They received for 1 year ibandronate daily (5 out of 7 days) at a dose of 0, 0.8, 1.2, 4.1, and 14 \u03bcg\/kg\/day or intermittently (65 \u03bcg\/kg\/day, 2 weeks on, 11 weeks off). Sham dogs received vehicle daily. At month 4, there was a significant decrease in bone volume in OHX animals (p &amp;lt; 0.05). Doses of ibandronate \u2265 4.1 \u03bcg\/kg\/day stopped or completely reversed bone loss. Bone turnover (activation frequency) was significantly depressed in OHX dogs given ibandronate at the dose of 14 \u03bcg\/kg\/day. This was accompanied by significantly higher crystal size, a higher mineral-to-matrix ratio, and a more uniformly mineralized bone matrix than in control dogs. This finding lends support to the hypothesis that an increase in secondary mineralization plays a role in gain in BMD associated with bisphosphonate treatment. Moreover, intermittent and continuous therapies had a similar effect on bone volume. However, intermittent therapy was more sparing on bone turnover and bone mineral properties. Intermittent therapy could therefore represent an attractive alternative approach to continuous therapy.<\/jats:p>","DOI":"10.1359\/jbmr.1999.14.10.1768","type":"journal-article","created":{"date-parts":[[2006,4,26]],"date-time":"2006-04-26T19:50:15Z","timestamp":1146081015000},"page":"1768-1778","source":"Crossref","is-referenced-by-count":74,"title":["Intermittent and Continuous Administration of the Bisphosphonate Ibandronate in Ovariohysterectomized Beagle Dogs: Effects on Bone Morphometry and Mineral Properties"],"prefix":"10.1093","volume":"14","author":[{"given":"Marie-Claude","family":"Monier-Faugere","sequence":"first","affiliation":[{"name":"Division of Nephrology, Bone and Mineral Metabolism, Department of Internal Medicine, University of Kentucky, Lexington, Kentucky, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaopo","family":"Geng","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Bone and Mineral Metabolism, Department of Internal Medicine, University of Kentucky, Lexington, Kentucky, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleftherios P.","family":"Paschalis","sequence":"additional","affiliation":[{"name":"Mineralized Tissue Section, Hospital for Special Surgery, New York, New York, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanle","family":"Qi","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Bone and Mineral Metabolism, Department of Internal Medicine, University of Kentucky, Lexington, Kentucky, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Illka","family":"Arnala","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Bone and Mineral Metabolism, Department of Internal Medicine, University of Kentucky, Lexington, Kentucky, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frieder","family":"Bauss","sequence":"additional","affiliation":[{"name":"Division of Preclinical Research and Development, Bone Metabolism, Boehringer Mannheim GmbH, Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adele L.","family":"Boskey","sequence":"additional","affiliation":[{"name":"Mineralized Tissue Section, Hospital for Special Surgery, New York, New York, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut H.","family":"Malluche","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Bone and Mineral Metabolism, Department of Internal Medicine, University of Kentucky, Lexington, Kentucky, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2009,12,2]]},"reference":[{"key":"2024020713344992400_bib1","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/978-3-642-77991-6_11","volume-title":"Physiology and Pharmacology of Bone Handbook of Experimental Pharmacology","author":"Fleisch","year":"1993"},{"key":"2024020713344992400_bib2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3109\/07853899708998743","article-title":"Bisphosphonates: Preclinical aspects and use in osteoporosis","volume":"29","author":"Fleisch","year":"1997","journal-title":"Ann Med"},{"key":"2024020713344992400_bib3","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/8756-3282(93)90240-B","article-title":"Effects of one-year cyclical treatment with clodronate on postmenopausal bone loss","volume":"14","author":"Giannini","year":"1993","journal-title":"Bone"},{"key":"2024020713344992400_bib4","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/jbmr.5650100505","article-title":"Cyclical clodronate is effective in preventing postmenopausal bone loss: A comparative study with transcutaneous hormone replacement therapy","volume":"10","author":"Filipponi","year":"1995","journal-title":"J Bone Miner Res"},{"key":"2024020713344992400_bib5","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/8756-3282(95)00442-4","article-title":"Cyclical intravenous clodronate in postmenopausal osteoporosis: Results of a long-term clinical trial","volume":"18","author":"Filipponi","year":"1996","journal-title":"Bone"},{"key":"2024020713344992400_bib6","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/0029-7844(96)00171-8","article-title":"Continuous and cyclical clodronate therapies and bone density in postmenopausal bone loss","volume":"88","author":"Giannini","year":"1996","journal-title":"Obstet Gynecol"},{"key":"2024020713344992400_bib7","first-page":"1595","article-title":"Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosis","volume":"79","author":"Reid","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"2024020713344992400_bib8","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/BF01623227","article-title":"Two years' effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in the postmenopause","volume":"4","author":"Thiebaud","year":"1994","journal-title":"Osteoporos Int"},{"key":"2024020713344992400_bib9","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1046\/j.1365-2265.1997.d01-1741.x","article-title":"Effects of prolonged bisphosphonate therapy and its discontinuation on bone mineral density in post-menopausal osteoporosis","volume":"46","author":"Orr-Walker","year":"1997","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2024020713344992400_bib10","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0378-5122(96)01118-8","article-title":"Cyclical pamidronate infusions in postmenopausal osteoporosis","volume":"25","author":"Peretz","year":"1996","journal-title":"Maturitas"},{"key":"2024020713344992400_bib11","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/BF01629581","article-title":"Role of oral pamidronate in preventing bone loss in postmenopausal women","volume":"6","author":"Lees","year":"1996","journal-title":"Osteoporos Int"},{"key":"2024020713344992400_bib12","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1172\/JCI116872","article-title":"The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates","volume":"92","author":"Balena","year":"1993","journal-title":"J Clin Invest"},{"key":"2024020713344992400_bib13","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/8756-3282(95)00436-X","article-title":"Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis","volume":"18","author":"Devogelaer","year":"1996","journal-title":"Bone"},{"key":"2024020713344992400_bib14","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0002-9343(99)80134-X","article-title":"Alendronate treatment of the postmenopausal osteoporotic woman: Effect of multiple dosages on bone mass and bone remodeling","volume":"99","author":"Chesnut","year":"1995","journal-title":"Am J Med"},{"key":"2024020713344992400_bib15","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","article-title":"Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis: The Alendronate Phase III Osteoporosis Treatment Study Group","volume":"333","author":"Liberman","year":"1995","journal-title":"N Engl J Med"},{"key":"2024020713344992400_bib16","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1001\/jama.1997.03540380073035","article-title":"Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups","volume":"277","author":"Karpf","year":"1997","journal-title":"JAMA"},{"key":"2024020713344992400_bib17","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/S0002-9343(96)00282-3","article-title":"Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis","volume":"101","author":"Tucci","year":"1996","journal-title":"Am J Med"},{"key":"2024020713344992400_bib18","first-page":"1535","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures","volume":"348","author":"Black","year":"1996","journal-title":"Fracture Intervention Trial Res Group. Lancet"},{"key":"2024020713344992400_bib19","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/8756-3282(95)00400-9","article-title":"Sustained response to intravenous alendronate in postmenopausal osteoporosis","volume":"17","author":"Vasikaran","year":"1995","journal-title":"Bone"},{"key":"2024020713344992400_bib20","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1200\/JCO.1997.15.3.955","article-title":"Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: A double-blind, placebo-controlled study","volume":"15","author":"Delmas","year":"1997","journal-title":"J Clin Oncol"},{"key":"2024020713344992400_bib21","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/S0140-6736(89)92927-9","article-title":"Prevention of postmenopausal bone loss by tiludronate","volume":"2","author":"Reginster","year":"1989","journal-title":"Lancet"},{"key":"2024020713344992400_bib22","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/8756-3282(92)90077-A","article-title":"Inhibition of bone resorption by the bisphosphonate BM 21.0955 is not associated with an alteration of the renal handling of calcium in rats infused with parathyroid hormone-related protein","volume":"13","author":"Rizzoli","year":"1992","journal-title":"Bone"},{"key":"2024020713344992400_bib23","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S8756-3282(97)00145-2","article-title":"Bisphosphonate tiludronate increases bone strength by improving mass and structure in established osteopenia after ovariectomy in rats","volume":"21","author":"Ohnishi","year":"1997","journal-title":"Bone"},{"key":"2024020713344992400_bib24","first-page":"1399","article-title":"The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women","volume":"76","author":"Harris","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"2024020713344992400_bib25","first-page":"1693","article-title":"Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment","volume":"79","author":"Garnero","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"2024020713344992400_bib26","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S8756-3282(95)00262-6","article-title":"Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis","volume":"17","author":"Adami","year":"1995","journal-title":"Bone"},{"key":"2024020713344992400_bib27","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1002\/jbmr.5650091121","article-title":"Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis","volume":"9","author":"Rossini","year":"1994","journal-title":"J Bone Miner Res"},{"key":"2024020713344992400_bib28","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1172\/JCI119668","article-title":"Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis","volume":"100","author":"Chavassieux","year":"1997","journal-title":"J Clin Invest"},{"key":"2024020713344992400_bib29","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1210\/jcem.80.12.8530584","article-title":"Skeletal metabolism in patients with osteoporosis after discontinuation of long-term treatment with oral pamidronate","volume":"80","author":"Landman","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"2024020713344992400_bib30","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial [see comments]","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA"},{"key":"2024020713344992400_bib31","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S8756-3282(97)00170-1","article-title":"Bone mineral density reflects bone mass but also the degree of mineralization of bone: Therapeutic implications","volume":"21","author":"Meunier","year":"1997","journal-title":"Bone"},{"key":"2024020713344992400_bib32","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S8756-3282(97)00018-5","article-title":"Mineralization of cancellous bone after alendronate and sodium fluoride treatment: A quantitative backscattered electron imaging study on minipig ribs","volume":"20","author":"Roschger","year":"1997","journal-title":"Bone"},{"key":"2024020713344992400_bib33","first-page":"S477","article-title":"Alendronate increases the mean degree of mineralization of bone and the uniformity of mineralization of bone in osteoporotic women","volume":"23","author":"Boivin","year":"1998","journal-title":"J Bone Miner Res"},{"key":"2024020713344992400_bib34","doi-asserted-by":"crossref","first-page":"195S","DOI":"10.1016\/S8756-3282(96)90165-9","article-title":"Current bone mineral density data on bisophosphonates in postmenopausal osteoporosis","volume":"19","author":"McClung","year":"1996","journal-title":"Bone"},{"key":"2024020713344992400_bib35","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0889-8529(05)70014-1","article-title":"Treatment of osteoporosis with bisphosphonates","volume":"27","author":"Watts","year":"1998","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2024020713344992400_bib36","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0002-9343(97)00249-0","article-title":"Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis","volume":"103","author":"Thiebaud","year":"1997","journal-title":"Am J Med"},{"key":"2024020713344992400_bib37","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/jbmr.5650060915","article-title":"BM 21.0955, a potent new bisphosphonate to inhibit bone resorption","volume":"6","author":"Muhlbauer","year":"1991","journal-title":"J Bone Miner Res"},{"key":"2024020713344992400_bib38","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1002\/jbmr.5650081109","article-title":"A new bisophosphonate, BM 21.0955, prevents bone loss associated with cessation of ovarian function in experimental dogs","volume":"8","author":"Monier-Faugere","year":"1993","journal-title":"J Bone Miner Res"},{"key":"2024020713344992400_bib39","first-page":"232","volume-title":"Fundamentals of Small Animals Surgery","author":"Leonard","year":"1968"},{"key":"2024020713344992400_bib40"},{"key":"2024020713344992400_bib41","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/jbmr.5650080613","article-title":"Development and characterization of polyclonal antiserum-based radioimmunoassay for dog osteocalcin","volume":"8","author":"Fanti","year":"1993","journal-title":"J Bone Miner Res"},{"key":"2024020713344992400_bib42","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1210\/jcem-53-4-709","article-title":"Detection and characterization of smal mid-region parathyroid hormone fragment (s) in normal and hyperparathyroid glands and sera by immunoextraction and region-specific radioimmunoassay","volume":"53","author":"Roos","year":"1981","journal-title":"J Clin Endocrinol Metab"},{"key":"2024020713344992400_bib43","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1093\/clinchem\/32.11.2060","article-title":"Assay of circulating 1,25-dihydroxyvitamin D involving a novel single cartridge extraction and purification procedure","volume":"32","author":"Hollis","year":"1986","journal-title":"Clin Chem"},{"key":"2024020713344992400_bib44","volume-title":"Atlas of Mineralized Bone Histology","author":"Malluche","year":"1986"},{"key":"2024020713344992400_bib45","first-page":"237","article-title":"A modification of the Masson trichrome technique for routine laboratory purposes","volume":"14","author":"Goldner","year":"1938","journal-title":"Am J Pathol"},{"key":"2024020713344992400_bib46","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0010-468X(81)90098-2","article-title":"A program package for quantitative analysis of histologic structure and remodeling dynamics of bone","volume":"13","author":"Manaka","year":"1981","journal-title":"Comput Programs Biomed"},{"key":"2024020713344992400_bib47","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/BF02411282","article-title":"A new semiautomatic method for quantitative static and dynamic bone histology","volume":"34","author":"Malluche","year":"1982","journal-title":"Calcif Tissue Int"},{"key":"2024020713344992400_bib48","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1002\/jbmr.5650061210","article-title":"A new method for measuring cancellous bone erosion depth: Application to the cellular mechanisms of bone loss in post-menopausal osteoporosis","volume":"6","author":"Cohen-Solal","year":"1991","journal-title":"J Bone Miner Res"},{"key":"2024020713344992400_bib49","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/jbmr.5650020617","article-title":"Bone histomorphometry: Standardization of nomenclature, symbols and units","volume":"6","author":"Parfitt","year":"1987","journal-title":"J Bone Miner Res"},{"key":"2024020713344992400_bib50","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/BF00369214","article-title":"FTIR microspectroscopic analysis of human osteonal bone","volume":"59","author":"Paschalis","year":"1996","journal-title":"Calcif Tissue Int"},{"key":"2024020713344992400_bib51","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/s002239900371","article-title":"FTIR microspectroscopic analysis of normal human cortical and trabecular bone","volume":"61","author":"Paschalis","year":"1997","journal-title":"Calcif Tissue Int"},{"key":"2024020713344992400_bib52","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s002239900372","article-title":"FTIR microspectroscopic analysis of human iliac crest biopsies from untreated osteoporotic bone","volume":"61","author":"Paschalis","year":"1997","journal-title":"Calcif Tissue Int"},{"key":"2024020713344992400_bib53","first-page":"189","volume-title":"Exploring data SPSS for Windows Base System User's Guide, Release 6.0","author":"Norusis","year":"1993"},{"key":"2024020713344992400_bib54","first-page":"S336","article-title":"Comparison of continuous and cyclical administration of ibandronate on bone mass in ovariectomized rats","volume":"11","author":"Bauss","year":"1996","journal-title":"J Bone Miner Res"},{"key":"2024020713344992400_bib55","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S8756-3282(96)00229-3","article-title":"The effect on bone mass and bone markers of different doses of ibandronate: A new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: A 1-year, randomized, double-blind, placebo-controlled dose-finding study","volume":"19","author":"Ravn","year":"1996","journal-title":"Bone"},{"key":"2024020713344992400_bib56","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/BF01320915","article-title":"Continuous alendronate treatment throughout growth, maturation, and aging in the rat results in increases in bone mass and mechanical properties","volume":"53","author":"Guy","year":"1993","journal-title":"Calcif Tissue Int"},{"key":"2024020713344992400_bib57","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1002\/jbmr.5650081212","article-title":"Effects of the bisphosphonate tiludronate on bone resorption, calcium balance, and bone mineral density","volume":"8","author":"Ammann","year":"1993","journal-title":"J Bone Miner Res"},{"key":"2024020713344992400_bib58","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1007\/BF01623003","article-title":"Short-term effect of alendronate on bone mass and bone remodeling in postmenopausal women","volume":"3","author":"Chesnut","year":"1993","journal-title":"Osteoporos Int"},{"key":"2024020713344992400_bib59","first-page":"271","article-title":"Long-term safety of the aminobisphosphonate alendronate in adult dogs. I. General safety and biomechanical properties of bone","volume":"276","author":"Peter","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"2024020713344992400_bib60","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s002239900098","article-title":"Increased bone resorption precedes increased bone formation in the ovariectomized rat","volume":"59","author":"Sims","year":"1996","journal-title":"Calcif Tissue Int"},{"key":"2024020713344992400_bib61","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/8756-3282(95)80027-N","article-title":"Temporal changes in cancellous bone structure of rats immediately after ovariectomy","volume":"16","author":"Dempster","year":"1995","journal-title":"Bone"},{"key":"2024020713344992400_bib62","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1359\/jbmr.1998.13.2.229","article-title":"Acute changes in trabecular bone connectivity and osteoclast activity in the ovariectomized rat in vivo","volume":"13","author":"Lane","year":"1998","journal-title":"J Bone Miner Res"},{"key":"2024020713344992400_bib63","doi-asserted-by":"crossref","DOI":"10.1359\/jbmr.1998.13.9.1451","article-title":"Variation in the short-term changes in bone cell activity in three regions of the distal femur immediately following ovariectomy","volume":"13","author":"Baldock","year":"1998","journal-title":"J Bone Miner Res"},{"key":"2024020713344992400_bib64","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/jbmr.5650050310","article-title":"Bone changes occurring early after cessation of ovarian function in beagle dogs: A histomorphometric study employing sequential biopsies","volume":"5","author":"Faugere","year":"1990","journal-title":"J Bone Miner Res"},{"key":"2024020713344992400_bib65","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S8756-3282(95)00150-6","article-title":"A possible mechanism of the specific action of bisphosphonates on osteoclasts: Tiludronate preferentially affects polarized osteoclasts having ruffled borders","volume":"17","author":"Murakami","year":"1995","journal-title":"Bone"},{"key":"2024020713344992400_bib66","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1172\/JCI118722","article-title":"Bisphosphonates: Mechanisms of action","volume":"97","author":"Rodan","year":"1996","journal-title":"J Clin Invest"},{"key":"2024020713344992400_bib67","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1172\/JCI116422","article-title":"Bisphosphonates act on rat bone resorption through the mediation of osteoblasts","volume":"91","author":"Sahni","year":"1993","journal-title":"J Clin Invest"},{"key":"2024020713344992400_bib68","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1210\/endo.137.6.8641182","article-title":"Bisphosphonates induce osteoblasts to secrete and inhibitor of osteoclast-mediated resorption","volume":"137","author":"Vitt\u00e9","year":"1996","journal-title":"Endocrinology"},{"key":"2024020713344992400_bib69","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/jbmr.5650100207","article-title":"The effects of risedronate on canine cancellous bone remodeling: Three- dimensional kinetic reconstruction of the remodeling site","volume":"10","author":"Boyce","year":"1995","journal-title":"J Bone Miner Res"},{"key":"2024020713344992400_bib70","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/jbmr.5650080211","article-title":"Changes in bone histomorphometry after long-term treatment with intermittent, cyclic etidronate for postmenopausal osteoporosis","volume":"8","author":"Storm","year":"1993","journal-title":"J Bone Miner Res"},{"key":"2024020713344992400_bib71","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0169-6009(08)80055-4","article-title":"Effects of two novel bisphosphonates on bone cells in vitro","volume":"26","author":"Evans","year":"1994","journal-title":"Bone Miner"},{"key":"2024020713344992400_bib72","first-page":"27","article-title":"Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix","volume":"1","author":"Boonekamp","year":"1986","journal-title":"Bone Miner"},{"key":"2024020713344992400_bib73","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/jbmr.5650080107","article-title":"Transient recruitment of osteoclasts and expression of their function in osteopetrotic (op\/op) mice by a single injection of macrophage colony-stimulating factor","volume":"8","author":"Kodama","year":"1993","journal-title":"J Bone Miner Res"},{"key":"2024020713344992400_bib74","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/jbmr.5650101008","article-title":"Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo","volume":"10","author":"Hughes","year":"1995","journal-title":"J Bone Miner Res"},{"key":"2024020713344992400_bib75","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s002239900505","article-title":"Comparison of cytotoxic effects of bisphosphonates in vitro and in vivo","volume":"63","author":"Ito","year":"1998","journal-title":"Calcif Tissue Int"},{"key":"2024020713344992400_bib76","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1172\/JCI115539","article-title":"Bisphosphonate action: Alendronate localization in rat bone and effects on osteoclast ultrastructure","volume":"88","author":"Sato","year":"1991","journal-title":"J Clin Invest"},{"key":"2024020713344992400_bib77","first-page":"10","article-title":"[Morphological studies of hydroxyapatite crystals exposed to disodium pamidronate]","volume":"57","author":"Hein","year":"1997","journal-title":"Medicina (B Aires)"},{"key":"2024020713344992400_bib78","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/jbmr.5650110214","article-title":"Effects of sodium fluoride and alendronate on the bone mineral in minipigs: A small-angle X-ray scattering and backscattered electron imaging study","volume":"11","author":"Fratzl","year":"1996","journal-title":"J Bone Miner Res"},{"key":"2024020713344992400_bib79","volume-title":"Physical Chemical Considerations in Bisphosphonate-Related Therapies","author":"Ebrahimpour","year":"1995"},{"key":"2024020713344992400_bib80","first-page":"S183","article-title":"Long-term treatment with alendronate prevents postmenopausal bone loss: Epic four-year results","volume":"23","author":"Ravn","year":"1998","journal-title":"Bone"},{"key":"2024020713344992400_bib81","first-page":"S402","article-title":"Effects of alendronate discontinuation on BMD in early postmenopausal women","volume":"23","author":"Wasnich","year":"1998","journal-title":"Bone"},{"key":"2024020713344992400_bib82","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/BF01623942","article-title":"The bisphosphonate ibandronate, given daily as well as discontinuously, decreases bone resorption and increases calcium retention as assessed by 45Ca kinetics in the intact rat","volume":"6","author":"Fleisch","year":"1996","journal-title":"Osteoporos Int"},{"key":"2024020713344992400_bib83","first-page":"S336","article-title":"Bone quality following long-term treatment of ibandronate in adult beagle dogs","volume":"11","author":"Bauss","year":"1996","journal-title":"J Bone Miner Res"},{"key":"2024020713344992400_bib84","first-page":"S596","article-title":"A randomized, parallel group study comparing the efficacy of continuous versus cyclic alendronate in the treatment of postmenopausal women with low bone mass","volume":"23","author":"Balske","year":"1998","journal-title":"Bone"},{"key":"2024020713344992400_bib85","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/8756-3282(89)90004-5","article-title":"Skeletal fluorosis: Histomorphometric analysis of bone changes and bone fluoride content in 29 patients","volume":"10","author":"Boivin","year":"1989","journal-title":"Bone"},{"key":"2024020713344992400_bib86","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1007\/BF01623781","article-title":"Fewer bone histomorphometric abnormalities with intermittent than with continuous slow-release sodium fluoride therapy","volume":"7","author":"Schnitzler","year":"1997","journal-title":"Osteoporos Int"},{"key":"2024020713344992400_bib87","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1002\/jbmr.5650061107","article-title":"X-ray microanalysis of fluoride distribution in microfracture calluses in cancellous iliac bone from osteoporotic patients treated with fluoride and untreated","volume":"6","author":"Boivin","year":"1991","journal-title":"J Bone Miner Res"},{"key":"2024020713344992400_bib88","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/8756-3282(86)90017-7","article-title":"Histomorphometric analysis of a calcaneal stress fracture: A possible complication of fluoride therapy for osteoporosis","volume":"7","author":"Schnitzler","year":"1986","journal-title":"Bone"},{"key":"2024020713344992400_bib89","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/BF02672503","article-title":"Lifelong administration of high doses of ibandronate increases bone mass and maintains bone quality of lumbar vertebrae in rats","volume":"8","author":"Lalla","year":"1998","journal-title":"Osteoporos Int"},{"key":"2024020713344992400_bib90","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/jbmr.5650110506","article-title":"Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injection","volume":"11","author":"Pecherstorfer","year":"1996","journal-title":"J Bone Miner Res"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1359%2Fjbmr.1999.14.10.1768","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/14\/10\/1768\/56599646\/5650141015.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/14\/10\/1768\/56599646\/5650141015.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T14:57:24Z","timestamp":1710341844000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/14\/10\/1768-1778\/7514850"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,10,1]]},"references-count":90,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2009,12,2]]},"published-print":{"date-parts":[[1999,10,1]]}},"URL":"https:\/\/doi.org\/10.1359\/jbmr.1999.14.10.1768","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[1999,10,1]]},"published":{"date-parts":[[1999,10,1]]}}}